Takeda Pharmaceutical is collaborating with Poseida Therapeutics in an effort to provide a safer alternative for the development of gene therapies through non-viral technologies.
In fact, currently, one of the obstacles in the advancement of these therapies is the safety risk associated with the viruses used to deliver them. Takeda is interested in Poseida’s non-viral technology for in vivo gene therapies that work directly inside the patient. Madhu Natarajan, head of Takeda’s rare disease drug discovery unit, said, “This partnership reinforces Takeda’s commitment to investing in next-generation gene therapy approaches that have the potential to deliver functional cures for patients with rare genetic and hematologic diseases.”
